Astria Therapeutics Inc (ATXS) - News Archive

Navenibart Shows Promise in Hereditary Angioedema: Unveiling Results from the ALPHA-STAR Phase 1b/2 Trial Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling. Re...

:Astria Therapeutics, Inc., a biopharmaceutical company, is forging a path towards revolutionizing treatments for allergic and immunologic diseases. The company recently announced promising results from two of its key c...

Unlocking Potential: Astria Therapeutics Utilises Inducement Grants to Drive Future Growth Astria Therapeutics, Inc. (Nasdaq: ATXS), a pioneering biopharmaceutical company renowned for its innovative work in developing...

A Step Forward in Dermatology: Astria Therapeutics New Data Shines Light Amid Financial ChallengesAmidst the picturesque autumn landscapes of Paris, the 2025 European Academy of Dermatology & Venereology (EADV) Congress...

Astria Therapeutics, Inc. (Nasdaq: ATXS), a burgeoning player in the biopharmaceutical sector, is steering through a financially challenging period while executing strategic initiatives to bolster its future. The compan...

Boston-based Astria Therapeutics, Inc. (Nasdaq: ATXS), a pioneering biopharmaceutical company dedicated to developing groundbreaking therapies aimed at combating allergic and immunologic diseases, has recently made sign...

Positive Results for Astria Therapeutics: A Beacon of Hope in HAE Treatment In the ever-evolving landscape of biopharmaceutical innovation, Astria Therapeutics, Inc. (NASDAQ:ATXS) has emerged as a noteworthy contender w...

In an exciting new development in the field of dermatological therapeutics, Astria Therapeutics Inc. (Nasdaq: ATXS) announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IN...

BOSTON, October 2024 Astria Therapeutics, Inc. (NASDAQ:ATXS), a leading biopharmaceutical company focusing on the development of transformative therapies for allergic and immunologic diseases, announced its financial re...

Hereditary angioedema (HAE) represents a significant challenge in the realm of allergic and immunological diseases, characterized by recurrent episodes of severe swelling in various tissues. Patients suffer from unpredi...

Astria Therapeutics, Inc. a biopharmaceutical company specialized in developing therapies for allergic and immunologic diseases, recently announced a significant milestone in its quest to improve patient outcomes in her...

CSIMarket.com is proud to present an article discussing the recent developments and updates from Astria Therapeutics, a leading biopharmaceutical company focused on developing life-changing therapies for allergic and im...

:This article provides a comprehensive overview of the preclinical profile of STAR-0310, a novel therapeutic candidate developed by Astria Therapeutics for the treatment of allergic and immunological dermatological dise...

:This article provides an in-depth analysis of the positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, in h...

:This article highlights the financial results and corporate updates of Astria Therapeutics, a leading biopharmaceutical company focusing on treatments for allergic and immunological diseases. The company reported robus...